Multiple myeloma (MM) is a plasma cell malignancy characterized by very complex cytogenetic and molecular genetic aberrations. Hyperdiploid karyotypes are characterized mainly by trisomies of chromosomes 3, 5, 7, 9, 11, 15, 19, and 21, non-hyperdiploid karytoypes typically have translocations involving the IGH locus at 14q32. The most frequent deletions are 13q, 17p and 1p32.
Deletions of chromosome 1p have been described in 7-15% of cases of myeloma with inconsistent clinical consequences. CDKN2C at 1p32.3 has been identified in myeloma cell lines as the potential target of the deletion. Gain of 1q is one of the most recurrent chromosomal aberrations in MM. Amplification and overexpression of the CKS1B gene in chromosome band 1q21 has been associated with an aggressive clinical course in MM.
Clinical Applications
- Multiple Myeloma and Plasma Cell Neoplasms (MM)